Free Trial

Entrada Therapeutics (TRDA) Competitors

Entrada Therapeutics logo
$5.80 -0.39 (-6.23%)
As of 12:24 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TRDA vs. KURA, XNCR, MRVI, CRMD, AVBP, PHAT, PVLA, ABUS, VIR, and DNA

Should you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include Kura Oncology (KURA), Xencor (XNCR), Maravai LifeSciences (MRVI), CorMedix (CRMD), ArriVent BioPharma (AVBP), Phathom Pharmaceuticals (PHAT), Palvella Therapeutics (PVLA), Arbutus Biopharma (ABUS), Vir Biotechnology (VIR), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry.

Entrada Therapeutics vs. Its Competitors

Kura Oncology (NASDAQ:KURA) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

86.4% of Entrada Therapeutics shares are owned by institutional investors. 6.4% of Kura Oncology shares are owned by insiders. Comparatively, 8.1% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kura Oncology has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -92.30%. Entrada Therapeutics' return on equity of -17.81% beat Kura Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Kura OncologyN/A -52.32% -29.59%
Entrada Therapeutics -92.30%-17.81%-14.55%

Entrada Therapeutics has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kura Oncology$53.88M16.04-$173.98M-$2.26-4.40
Entrada Therapeutics$210.78M1.05$65.63M-$1.78-3.26

Kura Oncology has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500.

In the previous week, Kura Oncology had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 1 mentions for Kura Oncology and 0 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.83 beat Kura Oncology's score of 0.30 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Kura Oncology Neutral
Entrada Therapeutics Positive

Kura Oncology presently has a consensus target price of $24.67, indicating a potential upside of 147.78%. Entrada Therapeutics has a consensus target price of $25.67, indicating a potential upside of 342.91%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Entrada Therapeutics is more favorable than Kura Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kura Oncology
2 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.63
Entrada Therapeutics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67

Summary

Entrada Therapeutics beats Kura Oncology on 11 of the 16 factors compared between the two stocks.

Get Entrada Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRDA vs. The Competition

MetricEntrada TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$220.44M$3.41B$6.09B$10.48B
Dividend YieldN/A2.29%5.73%4.78%
P/E Ratio-3.2622.5584.2227.04
Price / Sales1.05478.89606.15130.16
Price / Cash3.9046.9737.8662.13
Price / Book0.5110.4412.306.56
Net Income$65.63M-$52.47M$3.32B$276.88M
7 Day Performance-4.84%1.65%0.42%0.68%
1 Month Performance13.85%13.79%7.68%3.85%
1 Year Performance-67.13%12.10%71.71%34.63%

Entrada Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRDA
Entrada Therapeutics
3.2525 of 5 stars
$5.80
-6.2%
$25.67
+342.9%
-65.0%$220.44M$210.78M-3.26110
KURA
Kura Oncology
4.1424 of 5 stars
$9.72
-2.1%
$24.67
+153.7%
-44.6%$843.78M$53.88M-4.30130Gap Down
XNCR
Xencor
3.7307 of 5 stars
$11.67
-16.4%
$24.22
+107.6%
-30.5%$833.73M$110.49M-4.87280Analyst Forecast
MRVI
Maravai LifeSciences
3.7783 of 5 stars
$3.24
-2.0%
$5.22
+61.3%
-57.8%$826.09M$259.18M-2.38610News Coverage
Analyst Forecast
Options Volume
Gap Down
CRMD
CorMedix
3.3699 of 5 stars
$10.55
-0.2%
$18.00
+70.6%
-3.5%$822.60M$43.47M14.0530
AVBP
ArriVent BioPharma
1.5447 of 5 stars
$20.19
-3.4%
$39.14
+93.9%
-34.0%$822.15MN/A-5.0440
PHAT
Phathom Pharmaceuticals
2.982 of 5 stars
$11.57
-7.7%
$17.50
+51.3%
-19.2%$818.51M$55.25M-2.44110
PVLA
Palvella Therapeutics
1.7575 of 5 stars
$73.89
-3.1%
$75.50
+2.2%
N/A$817.22M$42.81M-6.11N/AShort Interest ↑
ABUS
Arbutus Biopharma
1.8347 of 5 stars
$4.21
-1.8%
$5.00
+18.9%
+7.4%$806.29M$6.17M-14.5090News Coverage
VIR
Vir Biotechnology
3.5317 of 5 stars
$5.74
-2.1%
$17.30
+201.7%
-26.3%$800.87M$74.21M-1.44580Analyst Forecast
Insider Trade
DNA
Ginkgo Bioworks
1.2358 of 5 stars
$13.47
+2.4%
$9.00
-33.2%
+82.4%$797.42M$230.82M-2.30640

Related Companies and Tools


This page (NASDAQ:TRDA) was last updated on 10/17/2025 by MarketBeat.com Staff
From Our Partners